UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: May 2018 (Report No. 1)
Commission File Number 001-35932
ARCTURUS THERAPEUTICS LTD.
(Translation of Registrant’s name into English)
10628 Science Center Drive, Suite 200
San Diego, California 92121
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-FxForm 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
On May 14, 2018, Arcturus Therapeutics Ltd. (the “Company”) announced the filing (on May 14, 2018) of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission. The press release is attached hereto as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | ARCTURUS THERAPEUTICS LTD. |
| | | | |
| | | | |
| Date: May 14, 2018 | By: | /s/ Mark Herbert | |
| | Name: | Mark Herbert | |
| | Title: | Interim President | |
Exhibit Index
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press Release issued by the Company on May 14, 2018, titled “Arcturus Therapeutics Files Form 20-F.” |
